

# Contribution of IL-17-producing $\gamma\delta$ T cells to the efficacy of anticancer chemotherapy

Yuting Ma,<sup>1,6</sup> Laetitia Aymeric,<sup>1,6</sup> Clara Locher,<sup>1,6</sup> Stephen R. Mattarollo,<sup>8</sup> Nicolas F. Delahaye,<sup>1</sup> Pablo Pereira,<sup>9</sup> Laurent Boucontet,<sup>9</sup> Lionel Apetoh,<sup>10,11,12</sup> François Ghiringhelli,<sup>10,11,12</sup> Noëlia Casares,<sup>13</sup> Juan José Lasarte,<sup>13</sup> Goro Matsuzaki,<sup>14</sup> Koichi Ikuta,<sup>15</sup> Bernard Ryffel,<sup>16</sup> Kamel Benlagha,<sup>17</sup> Antoine Tesnière,<sup>2</sup> Nicolas Ibrahim,<sup>5</sup> Julie Déchanet-Merville,<sup>18</sup> Nathalie Chaput,<sup>1,3</sup> Mark J. Smyth,<sup>8</sup> Guido Kroemer,<sup>2,4,19,20,21</sup> and Laurence Zitvogel<sup>1,3,7</sup>

<sup>1</sup>Institut National de la Santé et de la Recherche Médicale (INSERM) U1015, <sup>2</sup>INSERM U848, <sup>3</sup>Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, <sup>4</sup>Metabolomics Platform, <sup>5</sup>Department of BioPathology, Institut Gustave Roussy, 94800 Villejuif, France

<sup>6</sup>École Doctorale de Cancérologie de l'Université Paris-Sud XI, 94800 Villejuif, France

<sup>7</sup>Faculté de Médecine de l'Université Paris-Sud XI, 94270 Le Kremlin-Bicêtre, France

<sup>8</sup>Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, 3002, Victoria, Australia

<sup>9</sup>Développement des Lymphocytes, INSERM U668, Institut Pasteur, 75015 Paris, France

<sup>10</sup>INSERM U866, 21000 Dijon, France

<sup>11</sup>Department of Medical Oncology, Georges François Leclerc Center, 21000, Dijon, France

<sup>12</sup>Faculty of Medicine and Pharmacy, University of Burgundy, 21000 Dijon, France

<sup>13</sup>Division of Hepatology and Gene Therapy, Centre for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain

<sup>14</sup>Molecular Microbiology Group, COMB, Tropical Biosphere Research Center, University of the Ryukyus, Okinawa 903-0213, Japan

<sup>15</sup>Laboratory of Biological Protection, Department of Biological Responses, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan

<sup>16</sup>Molecular Immunology and Embryology, Centre National de la Recherche Scientifique (CNRS), IEM 2815, 45071 Orléans, France

<sup>17</sup>INSERM Unité 561/Groupe AVENIR, Hôpital Cochin St. Vincent de Paul, Université Descartes, 75014 Paris, France

<sup>18</sup>CNRS, UMR 5164, Université Bordeaux 2, 33076 Bordeaux, France

<sup>19</sup>Centre de Recherche des Cordeliers, 75006 Paris, France

<sup>20</sup>Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France

<sup>21</sup>Faculté de Médecine, Université Paris René Descartes, Paris, France

**By triggering immunogenic cell death, some anticancer compounds, including anthracyclines and oxaliplatin, elicit tumor-specific, interferon- $\gamma$ -producing CD8<sup>+</sup>  $\alpha\beta$  T lymphocytes (Tc1 CTLs) that are pivotal for an optimal therapeutic outcome. Here, we demonstrate that chemotherapy induces a rapid and prominent invasion of interleukin (IL)-17-producing  $\gamma\delta$  (V $\gamma$ 4<sup>+</sup> and V $\gamma$ 6<sup>+</sup>) T lymphocytes ( $\gamma\delta$  T17 cells) that precedes the accumulation of Tc1 CTLs within the tumor bed. In T cell receptor  $\delta^{-/-}$  or V $\gamma$ 4/6<sup>-/-</sup> mice, the therapeutic efficacy of chemotherapy was compromised, no IL-17 was produced by tumor-infiltrating T cells, and Tc1 CTLs failed to invade the tumor after treatment. Although  $\gamma\delta$  T17 cells could produce both IL-17A and IL-22, the absence of a functional IL-17A-IL-17R pathway significantly reduced tumor-specific T cell responses elicited by tumor cell death, and the efficacy of chemotherapy in four independent transplantable tumor models. Adoptive transfer of  $\gamma\delta$  T cells restored the efficacy of chemotherapy in IL-17A<sup>-/-</sup> hosts. The anticancer effect of infused  $\gamma\delta$  T cells was lost when they lacked either IL-1R1 or IL-17A. Conventional helper CD4<sup>+</sup>  $\alpha\beta$  T cells failed to produce IL-17 after chemotherapy. We conclude that  $\gamma\delta$  T17 cells play a decisive role in chemotherapy-induced anticancer immune responses.**

The current management of cancer patients relies upon the therapeutic use of cytotoxic agents that are supposed to directly destroy cancer cells through a diverse array of cell death pathways.

© 2011 Ma et al. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at <http://creativecommons.org/licenses/by-nc-sa/3.0/>).

## CORRESPONDENCE

Laurence Zitvogel:  
zitvogel@igr.fr  
OR  
Guido Kroemer:  
kroemer@orange.fr

Abbreviations used: AhR, aryl hydrocarbon receptor; BMDC, BM-derived DC; CIg, isotype control Ig; DX, doxorubicin;  $\gamma\delta$  T17, IL-17A-producing  $\gamma\delta$  T cell; MTX, mitoxantrone; OX, oxaliplatin; Tc1, IFN- $\gamma$ -producing CD8<sup>+</sup> T cell; TIL, tumor-infiltrating lymphocyte; TR, tumor regression.

Nonetheless, several lines of evidence point to a critical contribution of the host immune system to the therapeutic activity mediated by tumoricidal agents (Nowak et al., 2002, 2003). Indeed, in some instances, the cell death triggered by chemotherapy or radiotherapy allows recognition of dying (anthracycline-treated or irradiated) tumor cells by antigen-presenting cells, thus eliciting a tumor-specific cognate immune response for tumor resolution. Whether cell death is immunogenic or not depends on the presence of tumor-specific antigens, as well as on the lethal hit. Thus, oxaliplatin (OX) and anthracyclines induce immunogenic cell death, whereas other chemotherapeutic agents such as cisplatin and alkylating agents tend to induce nonimmunogenic cell death (Casares et al., 2005; Obeid et al., 2007). Stressed and dying tumor cells may emit a particular pattern of “danger signals,” and these cell death-associated molecules are either exposed on the surface of dying cells or secreted into the microenvironment. The combined action of “find-me” and “eat-me” signals, together with the release of hidden molecules that are usually secluded within live cells may influence the switch between silent corpse removal and inflammatory reactions that stimulate the cellular immune response (Zitvogel et al., 2010). We initially described the crucial importance of an eat-me signal represented by the early translocation of the endoplasmic reticulum resident calreticulin–ERp57 complex to the plasma membrane for the immunogenicity of tumor cell death (Obeid et al., 2007; Panaretakis et al., 2008, 2009). Next, we showed that the nuclear alarmin HMGB1 must be released into the tumor microenvironment to engage TLR4 on host DCs to facilitate antigen processing and presentation (Apetoh et al., 2007). We also reported that ATP released from dying tumor cells could trigger the purinergic P2RX7 receptor on host DC, stimulating the release of IL-1 $\beta$ , which in turn facilitates the priming of CD8<sup>+</sup> tumor-specific T cells for IFN- $\gamma$  production that is indispensable for the success of chemotherapy (Ghiringhelli et al., 2009).

Although the contribution of IFN- $\gamma$  to tumor surveillance and anticancer immune responses is clearly established, that of the IL-17A–IL-17R pathway remains controversial (Martin-Orozco and Dong, 2009; Muranski and Restifo, 2009; Ngiow et al., 2010). In tumor models where CD4<sup>+</sup> T cells are the source of IL-17, this cytokine could induce Th1-type chemokines, recruiting effector cells to the tumor microenvironment (Kryczek et al., 2009) or promote IL-6-mediated Stat3 activation, acting as a protumorigenic trigger (Kortylewski et al., 2009; Wang et al., 2009). Tumor-specific Th17 exhibited stronger therapeutic efficacy than Th1 cells upon adoptive transfer, and converted into effective IFN- $\gamma$  producers (Muranski et al., 2008) and/or triggered the expansion, differentiation, and tumor homing of tumor-specific CD8<sup>+</sup> T cells (Martin-Orozco et al., 2009). IL-17-producing CD8<sup>+</sup> T cells also reduced the volume of large established tumors and could differentiate into long-lasting IFN- $\gamma$  producers (Hinrichs et al., 2009). In contrast, Kwong et al. (2010) described a tumor-promoting, IL-17-producing TCR  $\alpha\beta$ <sup>+</sup>CD8<sup>+</sup> cell subset. Therefore, the heterogeneous source

(and perhaps the targets) of IL-17 in the tumor microenvironment may determine whether this cytokine negatively or positively affects tumor growth. Whether conventional anticancer therapies such as chemotherapy and radiotherapy modulate IL-17 secretion and/or Th17 polarization remains to be explored (Maniati et al., 2010).

Similarly, the contribution of  $\gamma\delta$  T cells in tumor immunosurveillance is still elusive (Hayday, 2009). In humans, V $\delta$ 1<sup>+</sup>  $\gamma\delta$  T cells have been shown to mediate immunosuppressive activities (Peng et al., 2007) or, on the contrary, to be associated with a reduced occurrence of cancers in transplanted patients bearing a CMV infection (Déchanet et al., 1999; Couzi et al., 2010) and with long-term relapse-free survival after BM transplantation (van Burik et al., 2007). V $\delta$ 2<sup>+</sup>  $\gamma\delta$  T cells can be activated by various synthetic ligands to produce Th1-like cytokines, exhibit cytotoxic functions against tumors (Kabelitz et al., 2007), and mediate antitumor effects in patients (Wilhelm et al., 2003; Dieli et al., 2007). Although various  $\gamma\delta$  T cell subsets are capable of producing IL-17 during microbial infection or autoimmune disorders of mice (Shibata et al., 2007; O’Brien et al., 2009), very little is known about the incidence and functional relevance of IL-17-producing  $\gamma\delta$  T cells (that we termed  $\gamma\delta$  T17) in cancer (Gonçalves-Sousa et al., 2010).  $\gamma\delta$  T17 cells have been reported to share most phenotypic markers with Th17 cells (expressing CCR6, ROR $\gamma$ t, aryl hydrocarbon receptor [AhR], IL-23R, IL-17A, and IL-22; Martin et al., 2009).  $\gamma\delta$  T17 cells depend upon TGF- $\beta$  but not IL-23 or IL-6 for their development and maintenance (Do et al., 2010) and can be activated by IL-1 $\beta$  plus IL-23 (Sutton et al., 2009). They are unrestricted by V $\gamma$  usage (although they are mostly V $\gamma$ 4 in the context of mycobacteria [Martin et al., 2009] and experimental autoimmune encephalitis [Sutton et al., 2009]). Recent work suggests that thymic selection does little to constrain  $\gamma\delta$  T cell antigen specificities, but instead determines their effector fate. When triggered through the TCR, ligand-experienced cells secrete IFN- $\gamma$ , whereas ligand-naïve  $\gamma\delta$  T cells produce IL-17 (Jensen et al., 2008). CD27<sup>+</sup>  $\gamma\delta$  thymocytes expressed LT $\beta$ R and genes associated with a Th1 phenotype, in contrast to CD27<sup>-</sup>  $\gamma\delta$  thymocytes which give rise to IL-17-producing  $\gamma\delta$  cells (Ribot et al., 2009).

Therapy-induced immunogenic tumor cell death that stimulates a therapeutic anticancer immune response can be expected to influence the composition and/or the architecture of tumor immune infiltrates, which in turn contribute to the control of residual tumor cells. Here, we demonstrate that both IL-17A/IL-17RA signaling and  $\gamma\delta$  T cells are required for optimal anticancer responses and that the source of IL-17A is the  $\gamma\delta$  T population during immunogenic chemotherapy and radiotherapy. We show that an early tumor infiltration by  $\gamma\delta$  T17 cells is a prerequisite for optimal tumor colonization of IFN- $\gamma$ -producing CD8<sup>+</sup> T cells.  $\gamma\delta$  T cell activation depends on IL-1R1 and IL-1 $\beta$  (but not IL-23) produced by DCs in response to immunogenic dying tumor cells. Finally, the adoptive transfer of WT  $\gamma\delta$  T17 cells can restore the therapeutic efficacy of anticancer chemotherapy that is compromised in IL-17A<sup>-/-</sup> hosts.

## RESULTS

### A marked Th1 pattern 8 d after chemotherapy

Anthracyclines induce immune responses that culminate in CD8<sup>+</sup> T cell- and IFN- $\gamma$ /IFN- $\gamma$ R-dependent antitumor effects (Ghiringhelli et al., 2009). To further study chemotherapy-induced immune effectors at the site of tumor retardation, we performed quantitative RT-PCR to compare the transcription profile of 40 immune gene products expressed in MCA205 tumors, which were controlled by the anthracycline doxorubicin (DX) 8 d after treatment (Fig. 1 A, top), with that of progressing, sham-treated (PBS) tumors (Fig. 1 A, bottom). Several Th1-related gene products were specifically induced in regressing tumors (Fig. 1 B). In particular, the Th1 transcription factors Eomes and Tbx21 (also called T-bet) and their target, IFN- $\gamma$ , were increased by 4–5 fold in DX versus PBS-treated tumors (Fig. 1 C, left). Unsupervised hierarchical clustering indicated that IFN- $\gamma$  production correlated with that of the quintessential Th1 transcription factor, Tbx21. By day 8, the protein levels of IFN- $\gamma$  also increased in DX-treated MCA205 sarcomas (Fig. 1 D, left). Other surrogate markers of Th1 responses (lymphotoxin- $\beta$ , Ccl5, Cxcl10, Cxcl9, and TNF) were also significantly induced at the mRNA level after DX treatment (Fig. 1, B and C, left). Another set of gene products was also overexpressed in the context of DX-induced tumor regression. These genes encoded IL-7R, IL-21, AhR, Cxcl2, and Foxp3, suggesting that inflammation and/or tissue repair occurred in the tumor bed (Fig. 1, B and C, right). Indeed, by day 3 after chemotherapy, the protein levels of the inflammatory cytokine IL-17 were significantly increased within tumor homogenates (Fig. 1 D, right).

Reinforcing this finding, we found that AhR, a sensor of small chemical compounds, is involved in the success of anthracycline-based therapy in this model. AhR is recognized as a transcriptional regulator for the optimal IL-17-associated immune response, promoting the differentiation and/or maintenance of IL-17-producing cells (Esser et al., 2009). CH-223191 is a pure antagonist of AhR because it does not have any agonist actions up to 100  $\mu$ M (Kim et al., 2006). Blocking AhR with CH-223191 markedly reduced the efficacy of DX on established cancers in vivo (Fig. S1 A). This contrasts with the observation that CH-223191 had no cell autonomous effects on the tumor cells, alone or in combination with anthracyclines (Fig. S1 B).

DX (compared with PBS) induced a threefold increase in the proportions of both IFN- $\gamma$ - and IL-17-producing tumor-infiltrating lymphocytes (TILs) as tested by flow cytometry (FACS; Fig. 1 E). To identify the cellular source of IFN- $\gamma$  and IL-17, TILs were immunophenotyped by cell surface staining and intracellular detection of the cytokines with FACS. Careful analyses revealed that the major source of IFN- $\gamma$  was CD8<sup>+</sup> T cells, whereas that of IL-17 was mostly TCR  $\delta$ <sup>+</sup> T cells rather than CD4<sup>+</sup> Th17 cells 8 d after chemotherapy in MCA205 sarcomas (Fig. 1 F). We further analyzed the IFN- $\gamma$  and IL-17 production by each subset of TILs. CD4<sup>+</sup> T cells could secrete IFN- $\gamma$ , but rarely IL-17.


CD8<sup>+</sup> T and  $\gamma\delta$  T cells were polarized to become potent producers of IFN- $\gamma$  and IL-17, respectively. DX-based chemotherapy substantially enhanced IFN- $\gamma$  production by CD8<sup>+</sup> and CD4<sup>+</sup> TILs, as well as IL-17 production by  $\gamma\delta$  TILs (Fig. 1 G).

### $\gamma\delta$ T17 cells preceded and predicted the accumulation of Tc1 CTLs in tumor beds after chemotherapy


Kinetic experiments revealed that  $\gamma\delta$  TILs invaded MCA205 tumor beds and produced IL-17 shortly after chemotherapy, with significant increases ( $\sim$ 9-fold) over the background 4 d after DX injection (Fig. 2 A, left).  $\gamma\delta$  TILs still rapidly divided (as indicated by the expression of Ki67) 8 d after DX treatment (Fig. 2 B). This early induction of IL-17-producing  $\gamma\delta$  T cells (Fig. 2 C, left) contrasted with the comparatively late induction of IFN- $\gamma$ -producing CD8<sup>+</sup> T cells, which emerged sharply 8 d after chemotherapy (Fig. 2 C, right) and rapidly proliferated (Fig. 2 B). Altogether, anthracyclines induced an early Th1-biased inflammation together with a marked Th1 polarization in MCA205 tumor beds, associated with a brisk infiltration of  $\gamma\delta$  T17 cells followed by Tc1 effectors.

To generalize these findings, we systematically immunophenotyped TILs in CT26 colon cancer treated by a single intratumoral injection of DX, which significantly retarded tumor growth (Fig. 3 A). Indeed, the majority of IL-17A<sup>+</sup> TILs were CD45<sup>+</sup>CD3<sup>bright</sup>. They failed to express CD4, but were positively stained with anti-TCR  $\delta$ -specific antibodies (Fig. S2 A). Consistently, chemotherapy dramatically increased the frequency of IFN- $\gamma$ -producing CD8<sup>+</sup> T lymphocytes (Tc1; Fig. 3 B) and IL-17A-producing  $\gamma\delta$  T cells ( $\gamma\delta$  T17; Fig. 3 C) in the tumor microenvironment. Next, we monitored transplantable TS/A mammary carcinomas treated with local radiotherapy, which operates in a T cell-dependent manner (Apetoh et al., 2007). Irradiation of TS/A tumors led either to tumor regression or to no response, and hence tumor progression (Fig. 3 D). An accumulation of both Tc1 (Fig. 3 E) and  $\gamma\delta$  T17 (Fig. 3 F) lymphocytes was found in those tumors that responded to radiotherapy, but not in those that continued to progress or in untreated controls. Importantly, in each of the three tumor models that we tested, a clear correlation was observed between tumor invading  $\gamma\delta$  T17 and Tc1 cells (Fig. 3 G).

$\gamma\delta$  T17 TILs were preponderantly CD44<sup>+</sup> CD62L<sup>-</sup> CD69<sup>+</sup> and Granzyme B<sup>+</sup>. They did not express CD24, c-kit, NKG2D, CD27 (a thymic determinant for IFN- $\gamma$ -producing  $\gamma\delta$  T cells; Ribot et al., 2009), SCART2 (a specific marker for peripheral IL-17-producing cells which can be down-regulated upon activation; Kisielow et al., 2008), or CD122 (a marker for self antigen-experienced  $\gamma\delta$  T cells with potential to produce IFN- $\gamma$  (Jensen et al., 2008; unpublished data). FACS indicated that  $\sim$ 60% of  $\gamma\delta$  T17 used V $\gamma$ 4 chain (nomenclature of V $\gamma$  genes according to Heilig and Tonegawa [1986]), but expression of V $\gamma$ 1 and V $\gamma$ 7 chain was rarely found (Fig. S2 B). We then sorted V $\gamma$ 1<sup>-</sup>V $\gamma$ 4<sup>-</sup>V $\gamma$ 7<sup>-</sup>  $\gamma\delta$  T17 TILs (Fig. S2 C) and performed single-cell PCRs and sequencing (Pereira and Boucontet, 2004) to examine their V $\gamma$  chain usage. The majority of these cells (21 of 23 clones) contained functional



**Figure 1. Th1 and Th17 immune response in tumors after chemotherapy.** (A) Mice bearing MCA205 tumors were treated with PBS (solid symbols) or DX (open symbols) intratumorally at day 7 after tumor inoculation. Tumor growth was monitored at the indicated time points. (B and C) 8 d after chemotherapy (day 15 after tumor inoculation), tumor homogenates in PBS and DX groups were tested by quantitative RT-PCR (qRT-PCR). (B) Fold changes of gene expression are shown as a heat map. (C) Th1- and Th17-related gene expression in DX versus PBS groups (with a fold change >2) are listed. (D) Measurements of IFN- $\gamma$  and IL-17A protein in tumor homogenates by ELISA at the indicated time points. (E and F) Single-cell suspension of MCA205 tumors (day 8 after DX) were analyzed by FACS. (E) Expression of IFN- $\gamma$  and IL-17A in TILs was tested by intracellular staining gated on live, CD45<sup>+</sup> and CD3<sup>+</sup> cells. (F) IFN- $\gamma$ <sup>+</sup> and IL-17A<sup>+</sup> cells were gated, and the proportions of CD3<sup>+</sup> CD8<sup>+</sup> cells and CD3<sup>+</sup> TCR  $\delta$ <sup>+</sup> cells were examined in DX-treated tumors. A typical dot plot analysis (left) and the absolute numbers of Th17 and  $\gamma\delta$  T17 cells in the whole tumors (right) are shown. (G) IFN- $\gamma$  and IL-17A production by total CD4<sup>+</sup>, CD8<sup>+</sup>, and TCR  $\delta$ <sup>+</sup> TILs. Representative FACS plots in DX-treated tumors (left) and the percentages in PBS- or DX-treated tumors (right) are shown. Each group contained at least five mice, and each experiment was performed at least twice, yielding similar results. Graphs depict mean  $\pm$  SEM of fold change of gene expression (C), protein content (D), percentages, or absolute numbers of positive cells (E and G). \*, P < 0.05; \*\*, P < 0.01; \*\*\*, P < 0.001.



**Figure 2.  $\gamma\delta$  T17 cells preceded Tc1 CTL into tumors after chemotherapy.** (A) The percentages of IL-17- and IFN- $\gamma$ -producing cells among all tumor infiltrating  $\gamma\delta$  T cells and CD8 $^+$  T cells, respectively, are plotted before and at the indicated time points after tumor inoculation. Mice were treated with PBS (filled symbols) or DX (open symbols) at day 7. (B) Ki67 expression on  $\gamma\delta$  T and CD8 $^+$  TILs 8 d after treatment. (C) The percentages of  $\gamma\delta$  T17 and Tc1 among all CD3 $^+$  TILs at the indicated time points after tumor inoculation. DX was given at day 7. These experiments were performed twice on 5–10 tumors at each time point. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .

V $\gamma$ 6 rearrangements identical to those found in fetal  $\gamma\delta$  T cells (Lafaille et al., 1989). These experiments show that most  $\gamma\delta$  T17 TILs express V $\gamma$ 4 or V $\gamma$ 6 chains (Fig. S2, D and E).

Thus, chemotherapy and radiotherapy could trigger the accumulation of cytokine producing TILs in the tumor bed. This applies to distinct subsets of  $\gamma\delta$  T cells that rapidly invaded tumor and become IL-17 producers, correlating with the accumulation of Tc1 cells, which contribute to the chemotherapy-induced anticancer immune response.

### The IL-17A–IL-17R pathway is involved in the immunogenicity of cell death

Because both Tc1 and  $\gamma\delta$  T17 cells accumulated within tumors after chemotherapy or radiotherapy in a coordinated fashion, we determined whether neutralizing their signature cytokines IFN- $\gamma$  and IL-17A could mitigate the efficacy of anticancer therapies. Antibody-mediated neutralization of either IFN- $\gamma$  or IL-17A negatively affected the growth-retarding effect of DX against MCA205 tumors (Fig. 4 A). The mandatory role of the IL-17A–IL-17RA pathway was confirmed using neutralizing anti-IL-17RA antibodies and IL-17A $^{-/-}$  mice in the same tumor model (Fig. 4 B), in DX-treated MCA2 sarcomas (Fig. 4 C), as well as in OX-treated, OVA-expressing EG7 thymomas or CT26 colon cancers (Fig. 4, D and E).

To rationalize the sequential recruitment of  $\gamma\delta$  T17 and Tc1 cells into the tumor bed after chemotherapy, we hypothesized that  $\gamma\delta$  T17 might act as helper cells for Tc1 priming. We previously reported that specific antitumor immune responses rely on Tc1 cells primed by tumor cells undergoing immunogenic cell death by using a system in which IFN- $\gamma$  production by OVA-specific T cells could be triggered by OX-treated EG7 cells (Ghiringhelli et al., 2009). We used this system to check whether IL-17 is involved in initiating the specific antitumor response, comparing normal WT with IL-17RA $^{-/-}$  mice. In this assay, the absence of IL-17A fully


abolished antigen-specific T cell priming in response to dying cells, yet had no negative effect on T cell priming by OVA holoprotein admixed with CpG oligodeoxynucleotides (Fig. 5 A, left). Consistently, a neutralizing anti-IL-17A antibody, but not the isotype control Ig (CIg), markedly impaired the OVA-specific T cell induced by OX-treated EG7 (Fig. 5 A, right). Because Th1/Tc1 immune responses against dying

tumor cells mediate a prophylactic protection against rechallenge with live tumor cells (Apetoh et al., 2007; Ghiringhelli et al., 2009), we addressed the functional relevance of the IL-17A–IL-17RA pathway in this setting. Subcutaneous injection of mitoxantrone (MTX)-treated MCA205 sarcoma cells could protect WT mice, but not athymic nude mice, against rechallenge with live MCA205 tumor cells (Fig. 5 B). The efficacy of this vaccination was attenuated in IL-17RA $^{-/-}$  mice. Because IL-17 was not significantly produced by CD4 $^+$  or CD8 $^+$  T cells, neither in tumor beds during chemotherapy (Fig. 1 G) nor in the tumor draining LNs (unpublished data), we refrained from investigating Th17 cells and rather focused on  $\gamma\delta$  T and NKT cells as potential IL-17 producers (Mills, 2008; Pichavant et al., 2008) that might contribute to the anticancer vaccination by dying tumor cells. Although CD1d $^{-/-}$  mice, which lack all NKT population (Godfrey et al., 2010), were undistinguishable from WT controls in their ability to resist live tumor cells rechallenge after a dying tumor cell vaccine, V $\gamma$ 4/6 $^{-/-}$  mice (Sunaga et al., 1997) exhibited a reduced capacity to mount this anticancer immune response (Fig. 5 B). These results suggest that IL-17A, IL-17R, and  $\gamma\delta$  T17 cells all play a partial role in the afferent phase of the immune response against dying tumor cells, which includes T cell priming for IFN- $\gamma$  production.

### IL-1 $\beta$ -dependent, but not IL-23-dependent, activation of $\gamma\delta$ T lymphocytes

The IL-1 $\beta$ –IL-1R1 pathway is mandatory for eliciting Tc1 immune responses and for the efficacy of chemotherapy (Ghiringhelli et al., 2009). Moreover, we found an IL-1-related gene expression signature after chemotherapy in tumor beds (Fig. 1 B), prompting us to address its role in the activation of  $\gamma\delta$  T17 cells.


To explore the molecular requirements for  $\gamma\delta$  T17 activation in situ, we sorted  $\gamma\delta$  T cells from the skin-draining LNs



**Figure 3. Recruitment of both Tc1 and  $\gamma\delta$  T17 cells in CT26 and TS/A tumors that correlate with better tumor control.** (A–C) CT26 colon cancer treated with anthracyclines. (A) Tumor size before and 8 d after treatment with PBS (filled symbols) or DX (open symbols). (B) The percentage of CD8<sup>+</sup> T cells among CD3<sup>+</sup> cells and of IFN- $\gamma$ -producing cells among CD8<sup>+</sup> T cells. (C) The percentage of  $\gamma\delta$  T cells among CD3<sup>+</sup> cells and of IL-17A-producing cells among CD3<sup>+</sup>  $\gamma\delta$  T cells. Data are presented as mean  $\pm$  SEM with five tumors/group. (D–F) TS/A mammary cancer treated with x rays. (D) Established TS/A tumors were treated with local irradiation (open symbols) on day 10. Mice were segregated into nonresponders (tumor progression [TP], triangles) and responders (tumor regression [TR], circles) 22 d after radiotherapy (n = 5). (E) The percentage of CD8<sup>+</sup> T cells among CD3<sup>+</sup> cells and of IFN- $\gamma$ -producing cells among CD8<sup>+</sup> T cells; (F) The percentage of  $\gamma\delta$  T cells among CD3<sup>+</sup> cells and of IL-17A-producing cells among CD3<sup>+</sup>  $\gamma\delta$  T cells are indicated as mean  $\pm$  SEM. (G) The correlation between the percentages of  $\gamma\delta$  T17 and Tc1 TILs in all tumors (treated or not) was plotted for MCA205, CT26, and TS/A tumors (each dot representing one mouse). Data are representative of two to three independent experiments. \*, P < 0.05; \*\*, P < 0.01; \*\*\*, P < 0.001.

of naive mice (around 1–2% of the LN T cell pool). Among these  $\gamma\delta$  T cells,  $\sim$ 70% harbored the V $\gamma$ 4 TCR. Moreover, these cells vigorously produced IL-17A (but not IFN- $\gamma$ ) upon stimulation with PMA/ionomycin (Fig. S2 F; Do et al., 2010). In contrast to Th17 cells (Ivanov et al., 2006), LN-resident  $\gamma\delta$  T cells failed to produce IL-17 in response to TGF- $\beta$  or IL-6 alone, or in combination with IL-1 $\beta$ . However, they potently secreted IL-17 and IL-22 in response to the combined stimulation of IL-1 $\beta$  plus IL-23 (unpublished data; Sutton et al., 2009). TCR engagement also synergized with IL-1 $\beta$  (and to a lesser extent with IL-23) to trigger IL-17 and IL-22 secretion by LN-resident  $\gamma\delta$  T cells (unpublished data). It is noteworthy that these stimuli specifically activated IL-17A, but not IFN- $\gamma$  production by  $\gamma\delta$  T cells. Because  $\gamma\delta$  T17 cells were activated (as indicated by their Ki67<sup>+</sup>, GzB<sup>+</sup>, CD69<sup>+</sup>, and IL-17<sup>+</sup> phenotype) after chemotherapy, we addressed whether dying tumor cells could directly promote the activation of  $\gamma\delta$  T17. Although DX-treated MCA205 cells failed to directly induce IL-17 secretion by  $\gamma\delta$  T cells, they did so indirectly.

Thus, BM-derived DCs (BMDCs) that had been loaded with DX-treated MCA205 (Fig. 5 C; or CT26, not depicted), but not with live tumor cells, produced IL-1 $\beta$  and markedly stimulated the release of IL-17 and IL-22 by  $\gamma\delta$  T cells (Fig. 5 C). As a quality control for in vitro-generated DCs, the expression of CD11c, MHC class II, CD11b, and F4/80 was assessed. Only qualified DC preparations that contain functional DCs (>80% CD11c<sup>+</sup>MHCII<sup>+</sup>) rather than macrophages (>70% CD11b<sup>+</sup>F4/80<sup>+</sup>CD11c<sup>-</sup>) could activate  $\gamma\delta$  T cells for IL-17A production when they encountered DX-treated tumor cells. CD11b<sup>+</sup>Gr1<sup>+</sup> neutrophils reportedly produce IL-17 and promote downstream IL-12/IFN- $\gamma$  contributing to reperfusion injury (Li et al., 2010). Interestingly, CD11b<sup>+</sup>Gr1<sup>+</sup> cells sorted from DX-treated tumor beds bearing the IL-1 $\beta$  messenger RNA failed to secrete IL-1 $\beta$  or IL-17A protein and failed to activate  $\gamma\delta$  T cells for IL-17A production in vitro (unpublished data). IL-17 production by  $\gamma\delta$  T cells was dependent on IL-1 $\beta$  because the IL-1R1 antagonist IL-1RA entirely abrogated the DC/ $\gamma\delta$  T cell cross talk in the presence



**Figure 4. A mandatory role for the IL-17A–IL-17RA pathway in the efficacy of chemotherapy.**

(A) Mice bearing established MCA205 sarcomas were treated with local PBS (filled symbols) or DX (open symbols) 7 d after tumor inoculation and with systemic neutralizing antibodies against mouse IFN- $\gamma$  (left), IL-17A (right), or control Ig (Clg) i.p. every 2 d (3 injections, 200  $\mu$ g/mouse) starting on the day of DX. (B–E) WT (circles or squares) or IL-17A<sup>-/-</sup> (triangles) mice bearing established MCA205 sarcomas (B), MCA2 (C), EG7 (D), or CT26 (E) tumors were treated with PBS (B–E, solid symbols), DX (B and C, open symbols), or OX (D and E, open symbols) together with systemic administration of neutralizing antibodies against IL-17RA (squares) or Clg. Tumor sizes are plotted as mean  $\pm$  SEM for 5–15 mice/group, and each experiment was repeated at least 2 times, yielding similar results. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .


#### $\gamma\delta$ T lymphocytes are indispensable for the immune-dependent effects of chemotherapy

To further evaluate the contribution of  $\gamma\delta$  T cells to the therapeutic action of DX on established MCA205 sarcomas, such tumors were implanted into age- and sex-matched WT, TCR  $\delta^{-/-}$ , V $\gamma$ 4/6<sup>-/-</sup> mice, and then subjected to chemotherapy. As compared with WT controls, the absence of the TCR  $\delta$  chain, as well as that of V $\gamma$ 4 and V $\gamma$ 6  $\gamma\delta$  T cells, greatly reduced the efficacy of chemotherapy (Fig. 6 A). At day 8 after chemotherapy, when  $\gamma\delta$  T17 and Tc1 massively infiltrated tumor beds in WT mice, these cytokine-producing TILs were either absent or greatly reduced in V $\gamma$ 4/6<sup>-/-</sup> mice (Fig. 6 B), suggesting that the presence of V $\gamma$ 4 and V $\gamma$ 6  $\gamma\delta$  T cells are critical for the optimal Tc1 response in tumor beds.

Expression of CCR6 is a phenotypic and functional hallmark of Th17 cells (Reboldi et al., 2009) during some inflammatory processes. We therefore analyzed the role of CCR6 in the efficacy of chemotherapy. Because CCL20 was detectable in tumor tissues before and after chemotherapy (unpublished data), we assessed whether  $\gamma\delta$  T17 cells could be recruited in a CCL20/CCR6-dependent manner. The tumoricidal activity of DX against CT26 was not affected by repetitive systemic injections of neutralizing anti-CCL20 antibody before and during anthracycline treatment (Fig. S3 B). Consistently, anthracycline treatment against established MCA205 sarcoma remained efficient in CCR6 loss-of-function mice. Moreover, CCR6 deficiency did not influence tumor infiltration by  $\gamma\delta$  T17 (unpublished data). Therefore, V $\gamma$ 4 and V $\gamma$ 6  $\gamma\delta$  T cells contribute to the immune-mediated action of anticancer agents in a CCR6-independent fashion.


Next, we determined the contribution of adoptively transferred  $\gamma\delta$  T cells to the efficacy of chemotherapy. The infusion of  $\gamma\delta$  T cells derived from skin-draining LNs (from naive

of dying cells. The neutralization of IL-18R, IL-23, or IL-23R failed to abolish IL-17 production by  $\gamma\delta$  T cells co-cultured with DCs (Fig. 5 D). IL-22 production was completely abolished by blocking the IL-1 $\beta$ –IL-1R or IL-23–IL-23R pathways but not affected by IL-18R blockade. Interestingly, chemotherapy lost part of its anticancer activity in IL-1R1-deficient mice, yet maintained its efficacy in mice treated with IL-23p19-neutralizing antibodies or in IL-23p19<sup>-/-</sup> mice (Fig. 5, E–G). IL-1 $\beta$ -activated  $\gamma\delta$  T cells produced IL-17 and IL-22 (Fig. 5, C and D). However, IL-22 did not play an essential role in the antitumor effects promoted by chemotherapy (Fig. S3 A). It is of note that the antibody we used in this experiment could block the bioactivity of IL-22 in a lung bacterial infection model (Aujla et al., 2008), and IL-22 mRNA in the bulk TILs was below the detection limit of quantitative RT-PCR. Collectively, these results underscore the importance of IL-1 $\beta$  and IL-17 for the immune-dependent anticancer effects of chemotherapy, yet suggest that both IL-23 and IL-22 are dispensable for such effects.



**Figure 5. Role of  $\gamma\delta$  T17 in the priming of T cell responses during an immunogenic cell death and regulation by IL-1 $\beta$ .** (A) OX-treated EG-7 cells were inoculated in the footpad of WT versus IL-17RA<sup>-/-</sup> mice ( $n = 5$ ; left) along with anti-IL-17A neutralizing antibody (or Clg; right panel). OVA-specific IFN- $\gamma$  secretion by draining LN cells was measured in vitro by ELISA after stimulation with OVA protein (1 mg/ml). OVA/CpG immunization was used as positive control. (B) Immunization with MTX-treated MCA205 and rechallenge with a tumorigenic dose of live MCA205 were performed at day 0 and day 7, respectively in WT C57Bl6 ( $n = 10$ ), nude ( $n = 10$ ), V $\gamma$ 4/6<sup>-/-</sup> ( $n = 15$ ), IL-17RA<sup>-/-</sup> ( $n = 8$ ), and CD1d<sup>-/-</sup> ( $n = 6$ ) mice. The percentages of tumor-free mice were scored at the indicated time points. Experiments in A and B were performed twice with similar results. (C) Production of IL-1 $\beta$ , IL-17A, and IL-22 from mixed co-cultures of LN-derived  $\gamma\delta$  T cells and/or BMDCs loaded or not loaded with live or DX-treated MCA205 was monitored by ELISA. Data are shown as mean  $\pm$  SEM (D) Co-cultures of DX-treated MCA205/BMDC/ $\gamma\delta$  T were performed in the presence of 20  $\mu$ g/ml IL-1RA (Amgen), anti-IL-23, or





**Figure 6. The therapeutic activity of anthracyclines and tumor colonization of Tc1 depend upon V $\gamma$ 4 V $\gamma$ 6  $\gamma\delta$  T cells.** (A) WT, TCR  $\delta^{-/-}$ , or V $\gamma$ 4/6 $^{-/-}$  mice with established MCA205 tumors were injected intratumorally with PBS or DX. Tumor size was measured at the indicated time and plotted as mean  $\pm$  SEM ( $n = 8$ /group). (B) Percentage of IL-17A- or IFN- $\gamma$ -expressing cells within CD3<sup>+</sup> TCR $\delta$ <sup>+</sup> and CD3<sup>+</sup> CD8<sup>+</sup> TILs, respectively, in WT or V $\gamma$ 4/6 $^{-/-}$  mice. A typical dot plot is shown (left) and statistical analysis was performed with combined data from two independent experiments (right). \*,  $P < 0.05$ ; \*\*\*,  $P < 0.001$ .


WT mice) into tumor beds 2 d after DX potentiated the growth-retarding effect of chemotherapy, yet had no effect on PBS-treated tumors (Fig. 7 A). Importantly, synergistic antitumor effects of DX and adoptively transferred  $\gamma\delta$  T cells were lost when the  $\gamma\delta$  T cells were obtained from IL-17A $^{-/-}$  or IL-1R1 $^{-/-}$  donors (Fig. 7, B and C), emphasizing the role of IL-1 $\beta$  responses and IL-17 production in the function of  $\gamma\delta$  T cells. Moreover, the adoptive transfer of WT  $\gamma\delta$  T cells could restore the antitumor efficacy of chemotherapy in IL-17A-deficient mice (Fig. 7 D). Collectively, these results emphasize the important contribution of  $\gamma\delta$  T17 cells to the immune-dependent effects of anticancer chemotherapy.

## DISCUSSION

Our results highlight a role of  $\gamma\delta$  T cells, particularly the V $\gamma$ 4- and V $\gamma$ 6-expressing subsets that produce the effector cytokine IL-17A, in the anticancer immune response induced by cytotoxic chemotherapeutics. We demonstrated that the IL-17A-IL-17RA signaling pathway is required for the priming of IFN- $\gamma$ -secreting, antigen-specific T cells by tumor cells exposed to chemotherapy. This tumor-specific, Tc1-mediated immune response is essential for anticancer immunity because the protective effect of dying tumor cell vaccination is lost in athymic nude mice or when CD8<sup>+</sup> T cells are depleted (Casares et al., 2005), and chemotherapy fails to work when the IFN- $\gamma$ -IFN- $\gamma$ R system is blocked (Ghiringhelli et al., 2009). Accordingly, we found that the absence of the IL-17A-IL-17RA pathway reduced the capacity of mice to mount a protective antitumor response.

When exploring the source of IL-17A elicited by dying tumor cells, we found that  $\gamma\delta$  T cells were the quantitatively and functionally most important IL-17A producers, based on several observations. First, in the context of chemotherapy, IL-17-producing cells accumulated in tumors, and most of them were positive for  $\gamma\delta$  T markers. Second, antigen-specific CD4<sup>+</sup> T cells in LNs draining the dying tumor cells showed a Th1 (IL-2 and IFN- $\gamma$ ) instead of a Th17 cytokine pattern (Ghiringhelli et al., 2009). CD4<sup>+</sup> and CD8<sup>+</sup> TILs were polarized to produce IFN- $\gamma$  instead of IL-17. Also, IL-6 and TGF- $\beta$ , two key regulatory cytokines essential for the differentiation of Th17 cells (Ivanov et al., 2006; Veldhoen et al., 2006), were dispensable for the efficacy of chemotherapy or vaccination with dying tumor cells (Fig. S3, C and D), suggesting that Th17 cells may not be required for the anticancer immune response after chemotherapy. Third, when popliteal LNs were recovered from mice that had been injected with dying (but not live) tumor cells through footpad, the restimulation of LN-resident cells using anti-CD3 $\epsilon$  plus IL-23 readily enhanced IL-17 production (unpublished data), a feature common to memory T cells (van Beelen et al., 2007), innate NKT (Rachitskaya et al., 2008), and  $\gamma\delta$  T cells (Sutton et al., 2009). Fourthly, the subset of NKT cells capable of producing IL-17 in LNs (CD103<sup>+</sup>CD4<sup>-</sup>NK1.1<sup>-</sup>CCR6<sup>+</sup>CD1d tetramer<sup>+</sup>; Doisne et al., 2009) did not appear to be specifically triggered by dying cells in vivo (unpublished data). Moreover, CD1d $^{-/-}$  mice, which lack NKT cells, were indistinguishable from WT mice when the efficacy of chemotherapy was assessed in prophylactic vaccination settings. Fifthly, knockout of V $\gamma$ 4/6 or TCR  $\delta$  attenuated the protective antitumor vaccination with dying tumor cells and reduced the efficacy of the anthracycline-based chemotherapy on established tumors. Finally, the adoptive transfer of WT  $\gamma\delta$  T cells into IL-17A $^{-/-}$  hosts could restore the clinical response to chemotherapy and improve

IL-23R neutralizing antibodies, or 10  $\mu$ g/ml IL-18BP. Experiments in C and D were repeated three to six times. (E and G) Tumor size was monitored in WT (circles), IL-1R1 $^{-/-}$  (diamonds), and IL-23p19 $^{-/-}$  (squares) mice treated with PBS (filled symbols) or DX (open symbols; E and F), or in WT mice treated with systemic anti-IL-23 neutralizing antibodies (squares) or Clg (circles; G). Data are representative of 2 experiments with 6–10 mice/group. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .



**Figure 7. Role of  $\gamma\delta$  T cell-derived IL-17A during chemotherapy.** CD3<sup>+</sup> TCR  $\delta^+$  or CD3<sup>+</sup> TCR  $\delta^-$  T cells from WT mice (A), CD3<sup>+</sup> TCR  $\delta^+$  T cells from IL-17A<sup>-/-</sup> (B), or IL-1R1<sup>-/-</sup> (C) mice were injected intratumorally into MCA205-bearing WT mice (A–C) or IL-17A<sup>-/-</sup> mice (D) 2 d after PBS or DX treatment. Tumor sizes are plotted as mean  $\pm$  SEM for five mice/group. Experiments were repeated two to three times with similar results. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .

the response in WT hosts, and this latter effect was lost when  $\gamma\delta$  T cells from IL-17A<sup>-/-</sup> (rather than WT) donors were used.

In the context of immunogenic chemotherapy, it appears clear that IL-1 $\beta$  plays a major role in stimulating IL-17 production and the anticancer function of  $\gamma\delta$  T cells. The key role of IL-1 $\beta$  in regulating  $\gamma\delta$  T cells function was shown by using IL-1RA in co-cultures of DCs/ $\gamma\delta$  T cells in the presence of dying tumor cells. Also,  $\gamma\delta$  T cells that lack IL-1R1 lose the capacity to amplify the tumoricidal action of anthracyclines. Interestingly, inflammasome-dependent IL-1 $\beta$  secretion from DCs was also found to be mandatory for the polarization of CD8<sup>+</sup> T cells toward a Tc1 pattern (Ghiringhelli et al., 2009), suggesting that a connection between DCs,  $\gamma\delta$  T17 cells, and Tc1 cells might be important for optimal anticancer immune responses. We noticed a strong correlation between  $\gamma\delta$  T17 and Tc1 cells after chemotherapy in three different tumor models. We also noticed that the production of IL-17 production preceded that of IFN- $\gamma$  by TILs. It is well possible that besides helping the development of Tc1 response,  $\gamma\delta$  T17 cells might enhance the chemoattraction of effector Tc1 into the tumor beds. These results are compatible with observations obtained in a cancer-unrelated context, microbial infection, in which  $\gamma\delta$  T17 associated with Th1 responses exert protective immune response (Umemura et al., 2007). As IL-17 could not directly induce IFN- $\gamma$  production or enhance proliferation of CD8<sup>+</sup> T cells (unpublished data), our

results imply a causal relationship between the presence of  $\gamma\delta$  T17 cells and the recruitment of antitumor effector Tc1 cells into tumor beds.

$\gamma\delta$  T cells represent a major source of IL-17 during lung infection by *Mycobacterium tuberculosis* (Lockhart et al., 2006; Umemura et al., 2007) and liver infection by *Lysteria* (Hamada et al., 2008).  $\gamma\delta$  T cell-derived IL-17 is critical for the recruitment of neutrophil recruitment into the peritoneal cavity after *Escherichia coli* inoculation (Shibata et al., 2007).  $\gamma\delta$  T cells can be directly stimulated through TLR2, TLR1, and/or dectin-1 in response to *Mycobacterium tuberculosis* and *Candida albicans* to produce IL-17 in synergy with IL-23 (Martin et al., 2009). As to the mechanisms that link chemotherapy-elicited tumor cell death to the accumulation of  $\gamma\delta$  T17 cells, our data suggest that IL-1 $\beta$  acts as a major trigger. One previous report demonstrated the pivotal function of IL-1 $\beta$  in regulating  $\gamma\delta$  T17 cells in experimental autoimmune encephalomyelitis (EAE; Sutton et al., 2009). In that model, IL-1 $\beta$  synergized with IL-23 to promote IL-17 production by  $\gamma\delta$  T, which in turn, stimulated the differentiation of pathogenic Th17 cells.

Our data can be interpreted to support the contention that the context and immune orchestration at the site of cell death may be critical for an optimal contribution of the immune system to the efficacy of anticancer therapies. The present data introduces the idea that  $\gamma\delta$  T17 cells are part of the innate immune response that facilitates the subsequent cognate anticancer T cell responses. It remains a formidable challenge for investigating further how the innate and cognate immune effectors develop a dialog within the three-dimensional architecture of the tumor composed of dying and live tumor cells, as well as multiple stromal elements. Should  $\gamma\delta$  T17 cells also be recruited into human tumor beds after chemotherapy, it would be of the utmost importance to determine their TCR V $\delta$  usage to propose combination therapy of phosphoantigens (for V $\delta$ 2<sup>+</sup>) or other ligands or innate cytokines (for V $\delta$ 2<sup>-</sup>) and anthracyclines to increase therapeutic benefit in neoadjuvant settings or prevent metastases.

## MATERIALS AND METHODS

**Mice.** WT C57BL/6 (H-2<sup>b</sup>) and BALB/c (H-2<sup>d</sup>) mice aged between 7 and 12 wk were purchased from Harlan. Nude mice were bred in the animal facility of Institut Gustave Roussy. TCR  $\delta^{-/-}$ , IL-1R1<sup>-/-</sup>, and IL-17RA<sup>-/-</sup> (H-2<sup>b</sup>) mice were bred at Cryopreservation, Distribution, Typage, et Archivage Animal (Orléans, France) by B. Ryffel (CNRS, Orleans, France) and P. Pereira (Institut Pasteur, Paris, France; TCR  $\delta^{-/-}$  was bred in the same manner). IL-23p19<sup>-/-</sup> and IL-17A<sup>-/-</sup> (H-2<sup>b</sup>) were provided by M.J. Smyth (Peter MacCallum Cancer Centre, Victoria, Australia). V $\gamma$ 4 $\gamma$ 6<sup>-/-</sup> mice (H-2<sup>b</sup>) were provided by G. Matsuzaki (University of the Ryukyus, Okinawa, Japan) and K. Ikuta (Kyoto University, Kyoto, Japan). CD1d<sup>-/-</sup> and CCR6<sup>-/-</sup> (H-2<sup>b</sup>) mice were bred at St. Vincent de Paul Hospital AP-HP (Paris, France) and provided by K. Benlagha. The experimental protocols were approved by the Animal Care and Use Committee in the animal facility of Institut Gustave Roussy.

**Cell lines and reagents.** CT26 (H-2<sup>d</sup>) colon cancer, MCA205 (H-2<sup>b</sup>) and MCA2 (H-2<sup>d</sup>) sarcoma, TS/A mammalian cancer (H-2<sup>d</sup>), and EG7 thymoma (H-2<sup>b</sup>) were cultured in RPMI 1640 containing 10% FBS, 2 mM L-glutamine, 100 IU/ml penicillin/streptomycin, 1 mM sodium pyruvate, and 10 mM

Hepes at 37°C, 5% CO<sub>2</sub>. All media were purchased from Invitrogen. Recombinant mouse IL-1β, IL-23, IL-6, TGF-β, and IL-18 BpD/Fc were purchased from R&D Systems. AhR antagonist CH223191 was obtained from EMD. DX hydrochloride (D1515), MTX dihydrochloride (M6545), and DiOC<sub>6</sub>(3) were obtained from Sigma-Aldrich. Mouse IL-17A, IL-1β, and IL-23p19 ELISA kits were purchased from eBioscience. Mouse ELISA kits and neutralizing antibody for IL-22 (AF582; AB108C as isotype control) were purchased from R&D system. Antibodies for CD45.2 (104), CD3ε (145-2C11), CD4 (GK1.5), CD8α (53-6.7), TCR δ (GL-3), CD69 (H1.2F3), IL-17A (TC11-18H10), or IFN-γ (XMG1.2) were purchased from BD or eBioscience. Anti-SCART2 polyclonal serum was provided by J. Kiselow (Swiss Federal Institute of Technology, Zurich, Switzerland). Neutralizing antibodies for IL-17A (MAB421), IFN-γ (XMG1.2), CCL20 (MAB760), IL-23 (AF1619), IL-23R (MAB1686), IL-6 (MAB406), and IL-22 (AF582) were purchased from R&D Systems. CpG oligodeoxynucleotide 1668 was obtained from MWG Biotech AG. Anti-TGF-β peptide P17 and control peptide were obtained from J.J. Lasarte (University of Navarra, Pamplona, Spain; Dotor et al., 2007),

**Tumor models and chemo/radiotherapy.** 8 × 10<sup>5</sup> MCA205, EG7, CT26, TS/A, or MCA2 tumor cells were inoculated s.c. near the thigh into syngeneic mice. Chemotherapy was performed in MCA205 and CT26 models by intratumoral injection of DX (2 mM, 50 μl) or OX (5 mg/kg body weight, i.p.) when tumors reached 25–45 mm<sup>2</sup>. Radiotherapy was performed by local x-ray irradiation (10 Gy; RT250; Phillips) at the unshielded tumor area when TS/A tumor reached 40–60 mm<sup>2</sup>.

**Gene expression assays.** Whole RNA was extracted using RNeasy Mini kit (QIAGEN) from tumor homogenates. 5 μg of RNA from each sample were reverse-transcribed using QuantiTect Reverse Transcription kit (QIAGEN). Gene expression assays were performed with custom TaqMan Low Density Arrays using StepOnePlus Real-Time PCR System. PPIA was chosen as the endogenous control to perform normalization between different samples.

**Tumor dissection and FACS analysis.** Tumor burdens were carefully removed, cut into small pieces, and digested in 400 U/ml Collagenase IV and 150 U/ml DNase I for 30 min at 37°C. Single-cell suspension was obtained by grinding the digested tissue and filtering through a 70-μm cell strainer. Cells were blocked with 10 μg/ml anti-CD16/CD32 (eBioscience) before surface staining (2.5 μg/ml of each antibody). LIVE/DEAD Fixable Dead Cell Stain kit (Invitrogen) was used to distinguish live and dead cells. For intracellular staining, freshly isolated cells were treated with 50 ng/ml PMA, 1 μg/ml ionomycin, and GolgiStop (BD) for 4 h at 37°C in RPMI containing 2% mouse serum (Janvier). Cells were then stained with anti-IFN-γ and anti-IL-17 using a Cytofix/Cytoperm kit (BD).

**Protein extraction.** Tumors were mechanically dissociated with lysis buffer (T-PER Tissue Protein Extraction Reagent; Thermo Fisher Scientific) containing protease inhibitor (complete Mini EDTA-free; Roche). Tumor lysate was then centrifuged at 10000 g for 5 min at 4°C to obtain supernatant.

**Purification and adoptive transfer of γδ T cells.** The skin-draining LNs (inguinal, popliteal, superficial cervical, axillary, and brachial LNs) were harvested from naive mice (8–12 wk). Dead cells were removed from single-cell suspension (Dead Cell Removal kit) before γδ T cell purification (TCRγ/δ<sup>+</sup> T Cell Isolation kit) using AutoMACS Separator (Miltenyi Biotec) with recommended programs. Purity of this isolation normally reached >95%. The TCR δ<sup>+</sup> CD3<sup>+</sup> cell fraction was also collected and used as control for some experiments. Day 2 after chemotherapy, 2.5 × 10<sup>5</sup> cells were injected directly into the tumor with insulin syringes for the adoptive transfer setting.

**T cell priming and tumor vaccination.** EG7 cells pretreated with 5 μg/ml OX overnight or left untreated were washed thoroughly and injected at 1 million/50 μl into the foodpad of naive syngeneic mice. CpG/OVA (5 μg CpG+1 mg OVA/mouse) and PBS injection were used as positive and negative controls. In some setting, neutralizing antibody (200 μg/mouse) for

IL-17A or CIg was injected i.p. 5 d later, the popliteal LN cells were harvested, seeded in a 96-well plate at 3 × 10<sup>5</sup>/well and restimulated with 1 mg/ml OVA protein. IFN-γ secretion was measured by OptEIA Mouse IFN-γ ELISA kit (BD). MCA205 cells were treated with 2 μM MTX overnight, washed thoroughly, and injected into left flank s.c. at 3 × 10<sup>5</sup>/mouse. PBS was used as control. Mice were rechallenged with 5 × 10<sup>4</sup> live MCA205 cells in the right flank 7 d later. Tumor growth was monitored every 2–3 d.

**DC-tumor mixed lymphocyte cultures.** DCs were propagated in Iscove's medium (Sigma-Aldrich) with J558 supernatant (40 ng/ml GM-CSF), 10% FCS, 100 IU/ml penicillin/streptomycin, 2 mM L-glutamine, 50 μM 2-mercaptoethanol (Sigma-Aldrich) and used between day 8 and 12 when the proportion of CD11c/MHC class II<sup>+</sup> cells was >80%. In mixed co-cultures, DCs were seeded at 10<sup>5</sup>/100 μl/well in U-bottom 96-well plates. Tumor cells were treated overnight with 25 μM DX or left untreated, washed, and used at 7.5 × 10<sup>4</sup>/100 μl/well. 2 × 10<sup>4</sup>/50 μl γδ T cells were added 12 h later. Supernatant was collected 36 h later.

**Statistical analyses of experimental data.** All results are expressed as mean ± SEM, or as ranges when appropriate. For two groups, normal distributions were compared by unpaired Student's *t* test. Non-normal samplings were compared using the Mann-Whitney test or Wilcoxon matched paired test when appropriate. The log-rank test was used for analysis of Kaplan-Meier survival curve. Statistical analyses were performed using Prism 5 software (GraphPad). P values of <0.05 were considered significant.

**Online supplemental material.** Fig. S1 shows the effect of AhR antagonist on the efficacy of chemotherapy (DX). Fig. S2 depicts the Vγ chain usage of tumor-infiltrating γδ T17 and γδ T cells in the LNs of naive mice. Fig. S3 shows the effect of neutralizing IL-22, CCL20, IL-6, or blocking TGF-β on the efficacy of chemotherapy or vaccine. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20100269/DC1>.

This work was supported by LIGUE labellisée (L. Zitvogel and G. Kroemer), INFLACARE FP7 EU grant, INCa, Fondation pour la Recherche Médicale, and Fondation de France. Y. Ma was supported by the China Scholarship Council. N.F. Delahaye was supported by INCa and INFLACARE FP7. L. Apetoh was supported by the Agence Nationale pour la Recherche [ANR-10-PDOC-014-01].

The authors have no conflicting financial interests.

Submitted: 8 February 2010

Accepted: 4 February 2011

## REFERENCES

- Apetoh, L., F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz, A. Criollo, G. Mignot, M.C. Maiuri, E. Ullrich, P. Saulnier, et al. 2007. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. *Nat. Med.* 13:1050–1059. doi:10.1038/nm1622
- Aujla, S.J., Y.R. Chan, M. Zheng, M. Fei, D.J. Askew, D.A. Pociask, T.A. Reinhart, F. McAllister, J. Edeal, K. Gaus, et al. 2008. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. *Nat. Med.* 14:275–281. doi:10.1038/nm1710
- Casares, N., M.O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux, N. Chaput, E. Schmitt, A. Hamai, S. Hervas-Stubbs, M. Obeid, et al. 2005. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. *J. Exp. Med.* 202:1691–1701. doi:10.1084/jem.20050915
- Couzi, L., Y. Levaillant, A. Jamaï, V. Pitard, R. Lassalle, K. Martin, I. Garrigue, O. Hawchar, F. Siberchicot, N. Moore, et al. 2010. Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation. *J. Am. Soc. Nephrol.* 21:181–188. doi:10.1681/ASN.2008101072
- Déchanet, J., P. Merville, A. Lim, C. Retière, V. Pitard, X. Lafarge, S. Michelon, C. Méric, M.M. Hallet, P. Kourilsky, et al. 1999. Implication of gammadelta T cells in the human immune response to cytomegalovirus. *J. Clin. Invest.* 103:1437–1449. doi:10.1172/JCI5409
- Dieli, F., D. Vermijlen, F. Fulfaro, N. Caccamo, S. Meraviglia, G. Cicero, A. Roberts, S. Buccheri, M. D'Asaro, N. Gebbia, et al. 2007. Targeting

- human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. *Cancer Res.* 67:7450–7457. doi:10.1158/0008-5472.CAN-07-0199
- Do, J.S., P.J. Fink, L. Li, R. Spolski, J. Robinson, W.J. Leonard, J.J. Letterio, and B. Min. 2010. Cutting edge: spontaneous development of IL-17-producing gamma delta T cells in the thymus occurs via a TGF-beta 1-dependent mechanism. *J. Immunol.* 184:1675–1679. doi:10.4049/jimmunol.0903539
- Doisne, J.M., C. Becourt, L. Amniai, N. Duarte, J.B. Le Ludeuc, G. Eberl, and K. Benlagha. 2009. Skin and peripheral lymph node invariant NKT cells are mainly retinoic acid receptor-related orphan receptor (gamma)++ and respond preferentially under inflammatory conditions. *J. Immunol.* 183:2142–2149. doi:10.4049/jimmunol.0901059
- Dotor, J., A.B. López-Vázquez, J.J. Lasarte, P. Sarobe, M. García-Granero, J.I. Riezu-Boj, A. Martínez, E. Feijó, J. López-Sagasetta, J. Hermida, et al. 2007. Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library. *Cytokine.* 39:106–115. doi:10.1016/j.cyt.2007.06.004
- Esser, C., A. Rannug, and B. Stockinger. 2009. The aryl hydrocarbon receptor in immunity. *Trends Immunol.* 30:447–454. doi:10.1016/j.it.2009.06.005
- Ghiringhelli, F., L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma, C. Ortiz, K. Vermaelen, T. Panaretakis, G. Mignot, E. Ullrich, et al. 2009. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. *Nat. Med.* 15:1170–1178. doi:10.1038/nm.2028
- Godfrey, D.I., D.G. Pellicci, O. Patel, L. Kjer-Nielsen, J. McCluskey, and J. Rossjohn. 2010. Antigen recognition by CD1d-restricted NKT T cell receptors. *Semin. Immunol.* 22:61–67.
- Gonçalves-Sousa, N., J.C. Ribot, A. deBarros, D.V. Correia, I. Caramalho, and B. Silva-Santos. 2010. Inhibition of murine gammadelta lymphocyte expansion and effector function by regulatory alphabeta T cells is cell-contact-dependent and sensitive to GITR modulation. *Eur. J. Immunol.* 40:61–70.
- Hamada, S., M. Umemura, T. Shiono, K. Tanaka, A. Yahagi, M.D. Begum, K. Oshiro, Y. Okamoto, H. Watanabe, K. Kawakami, et al. 2008. IL-17A produced by gammadelta T cells plays a critical role in innate immunity against *Listeria monocytogenes* infection in the liver. *J. Immunol.* 181:3456–3463.
- Hayday, A.C. 2009. Gammadelta T cells and the lymphoid stress-surveillance response. *Immunity.* 31:184–196. doi:10.1016/j.immuni.2009.08.006
- Heilig, J.S., and S. Tonegawa. 1986. Diversity of murine gamma genes and expression in fetal and adult T lymphocytes. *Nature.* 322:836–840. doi:10.1038/322836a0
- Hinrichs, C.S., A. Kaiser, C.M. Paulos, L. Cassard, L. Sanchez-Perez, B. Heemskerk, C. Wrzesinski, Z.A. Borman, P. Muranski, and N.P. Restifo. 2009. Type 17 CD8+ T cells display enhanced antitumor immunity. *Blood.* 114:596–599. doi:10.1182/blood-2009-02-203935
- Ivanov, I.I., B.S. McKenzie, L. Zhou, C.E. Tadokoro, A. Lepelley, J.J. Lafaille, D.J. Cua, and D.R. Littman. 2006. The orphan nuclear receptor RORgamma directs the differentiation program of proinflammatory IL-17+ T helper cells. *Cell.* 126:1121–1133. doi:10.1016/j.cell.2006.07.035
- Jensen, K.D., X. Su, S. Shin, L. Li, S. Youssef, S. Yamasaki, L. Steinman, T. Saito, R.M. Locksley, M.M. Davis, et al. 2008. Thymic selection determines gammadelta T cell effector fate: antigen-naïve cells make interleukin-17 and antigen-experienced cells make interferon gamma. *Immunity.* 29:90–100. doi:10.1016/j.immuni.2008.04.022
- Kabelitz, D., D. Wesch, and W. He. 2007. Perspectives of gammadelta T cells in tumor immunology. *Cancer Res.* 67:5–8. doi:10.1158/0008-5472.CAN-06-3069
- Kim, S.H., E.C. Henry, D.K. Kim, Y.H. Kim, K.J. Shin, M.S. Han, T.G. Lee, J.K. Kang, T.A. Gasiewicz, S.H. Ryu, and P.G. Suh. 2006. Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. *Mol. Pharmacol.* 69:1871–1878. doi:10.1124/mol.105.021832
- Kisielow, J., M. Kopf, and K. Karjalainen. 2008. SCART scavenger receptors identify a novel subset of adult gammadelta T cells. *J. Immunol.* 181:1710–1716.
- Kortylewski, M., H. Xin, M. Kujawski, H. Lee, Y. Liu, T. Harris, C. Drake, D. Pardoll, and H. Yu. 2009. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. *Cancer Cell.* 15:114–123. doi:10.1016/j.ccr.2008.12.018
- Kryczek, I., M. Banerjee, P. Cheng, L. Vatan, W. Szeliga, S. Wei, E. Huang, E. Finlayson, D. Simeone, T.H. Welling, et al. 2009. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. *Blood.* 114:1141–1149. doi:10.1182/blood-2009-03-208249
- Kwong, B.Y., S.J. Roberts, T. Silberzahn, R.B. Filler, J.H. Neustadter, A. Galan, S. Reddy, W.M. Lin, P.D. Ellis, C.F. Langford, et al. 2010. Molecular analysis of tumor-promoting CD8+ T cells in two-stage cutaneous chemical carcinogenesis. *J. Invest. Dermatol.* 130:1726–1736. doi:10.1038/jid.2009.362
- Lafaille, J.J., A. DeCloux, M. Bonneville, Y. Takagaki, and S. Tonegawa. 1989. Junctional sequences of T cell receptor gamma delta genes: implications for gamma delta T cell lineages and for a novel intermediate of V-(D)-J joining. *Cell.* 59:859–870. doi:10.1016/0092-8674(89)90609-0
- Li, L., L. Huang, A.L. Vergis, H. Ye, A. Bajwa, V. Narayan, R.M. Strieter, D.L. Rosin, and M.D. Okusa. 2010. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. *J. Clin. Invest.* 120:331–342. doi:10.1172/JCI38702
- Lockhart, E., A.M. Green, and J.L. Flynn. 2006. IL-17 production is dominated by gammadelta T cells rather than CD4+ T cells during *Mycobacterium tuberculosis* infection. *J. Immunol.* 177:4662–4669.
- Maniati, E., R. Soper, and T. Hagemann. 2010. Up for Mischief? IL-17/Th17 in the tumour microenvironment. *Oncogene.* 29:5653–5662. doi:10.1038/onc.2010.367
- Martin, B., K. Hirota, D.J. Cua, B. Stockinger, and M. Veldhoen. 2009. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. *Immunity.* 31:321–330. doi:10.1016/j.immuni.2009.06.020
- Martin-Orozco, N., and C. Dong. 2009. The IL-17/IL-23 axis of inflammation in cancer: friend or foe? *Curr. Opin. Investig. Drugs.* 10:543–549.
- Martin-Orozco, N., P. Muranski, Y. Chung, X.O. Yang, T. Yamazaki, S. Lu, P. Hwu, N.P. Restifo, W.W. Overwijk, and C. Dong. 2009. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. *Immunity.* 31:787–798. doi:10.1016/j.immuni.2009.09.014
- Mills, K.H. 2008. Induction, function and regulation of IL-17-producing T cells. *Eur. J. Immunol.* 38:2636–2649. doi:10.1002/eji.200838535
- Muranski, P., and N.P. Restifo. 2009. Does IL-17 promote tumor growth? *Blood.* 114:231–232. doi:10.1182/blood-2009-04-215541
- Muranski, P., A. Boni, P.A. Antony, L. Cassard, K.R. Irvine, A. Kaiser, C.M. Paulos, D.C. Palmer, C.E. Touloukian, K. Ptak, et al. 2008. Tumor-specific Th17-polarized cells eradicate large established melanoma. *Blood.* 112:362–373. doi:10.1182/blood-2007-11-120998
- Ngiow, S.F., M.J. Smyth, and M.W. Teng. 2010. Does IL-17 suppress tumor growth? *Blood.* 115:2554–2555, author reply :2556–2557. doi:10.1182/blood-2009-11-254607
- Nowak, A.K., B.W. Robinson, and R.A. Lake. 2002. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. *Cancer Res.* 62:2353–2358.
- Nowak, A.K., R.A. Lake, A.L. Marzo, B. Scott, W.R. Heath, E.J. Collins, J.A. Frelinger, and B.W. Robinson. 2003. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. *J. Immunol.* 170:4905–4913.
- O'Brien, R.L., C.L. Roark, and W.K. Born. 2009. IL-17-producing gammadelta T cells. *Eur. J. Immunol.* 39:662–666. doi:10.1002/eji.200839120
- Obeid, M., A. Tesniere, F. Ghiringhelli, G.M. Fimia, L. Apetoh, J.L. Perfettini, M. Castedo, G. Mignot, T. Panaretakis, N. Casares, et al. 2007. Calreticulin exposure dictates the immunogenicity of cancer cell death. *Nat. Med.* 13:54–61. doi:10.1038/nm1523
- Panaretakis, T., N. Joza, N. Modjtahedi, A. Tesniere, I. Vitale, M. Durchschlag, G.M. Fimia, O. Kepp, M. Piacentini, K.U. Froehlich, et al. 2008. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. *Cell Death Differ.* 15:1499–1509. doi:10.1038/cdd.2008.67
- Panaretakis, T., O. Kepp, U. Brockmeier, A. Tesniere, A.C. Bjorklund, D.C. Chapman, M. Durchschlag, N. Joza, G. Pierron, P. van Ender, et al. 2009.

- Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. *EMBO J.* 28:578–590. doi:10.1038/emboj.2009.1
- Peng, G., H.Y. Wang, W. Peng, Y. Kiniwa, K.H. Seo, and R.F. Wang. 2007. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. *Immunity.* 27:334–348. doi:10.1016/j.immuni.2007.05.020
- Pereira, P., and L. Boucontet. 2004. Rates of recombination and chain pair biases greatly influence the primary gammadelta TCR repertoire in the thymus of adult mice. *J. Immunol.* 173:3261–3270.
- Pichavant, M., S. Goya, E.H. Meyer, R.A. Johnston, H.Y. Kim, P. Matangkasombut, M. Zhu, Y. Iwakura, P.B. Savage, R.H. DeKruyff, et al. 2008. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. *J. Exp. Med.* 205:385–393. doi:10.1084/jem.20071507
- Rachitskaya, A.V., A.M. Hansen, R. Horai, Z. Li, R. Villasmil, D. Luger, R.B. Nussenblatt, and R.R. Caspi. 2008. Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. *J. Immunol.* 180:5167–5171.
- Reboldi, A., C. Coisne, D. Baumjohann, F. Benvenuto, D. Bottinelli, S. Lira, A. Uccelli, A. Lanzavecchia, B. Engelhardt, and F. Sallusto. 2009. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. *Nat. Immunol.* 10:514–523. doi:10.1038/ni.1716
- Ribot, J.C., A. deBarros, D.J. Pang, J.F. Neves, V. Peperzak, S.J. Roberts, M. Girardi, J. Borst, A.C. Hayday, D.J. Pennington, and B. Silva-Santos. 2009. CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets. *Nat. Immunol.* 10:427–436. doi:10.1038/ni.1717
- Shibata, K., H. Yamada, H. Hara, K. Kishihara, and Y. Yoshikai. 2007. Resident Vdelta1+ gammadelta T cells control early infiltration of neutrophils after *Escherichia coli* infection via IL-17 production. *J. Immunol.* 178:4466–4472.
- Sunaga, S., K. Maki, Y. Komagata, J. Miyazaki, and K. Ikuta. 1997. Developmentally ordered V-J recombination in mouse T cell receptor gamma locus is not perturbed by targeted deletion of the Vgamma4 gene. *J. Immunol.* 158:4223–4228.
- Sutton, C.E., S.J. Lalor, C.M. Sweeney, C.F. Brereton, E.C. Lavelle, and K.H. Mills. 2009. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. *Immunity.* 31:331–341. doi:10.1016/j.immuni.2009.08.001
- Umemura, M., A. Yahagi, S. Hamada, M.D. Begum, H. Watanabe, K. Kawakami, T. Suda, K. Sudo, S. Nakae, Y. Iwakura, and G. Matsuzaki. 2007. IL-17-mediated regulation of innate and acquired immune response against pulmonary *Mycobacterium bovis* bacille Calmette-Guerin infection. *J. Immunol.* 178:3786–3796.
- van Beelen, A.J., Z. Zelinkova, E.W. Taanman-Kueter, F.J. Muller, D.W. Hommes, S.A. Zaai, M.L. Kapsenberg, and E.C. de Jong. 2007. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. *Immunity.* 27:660–669. doi:10.1016/j.immuni.2007.08.013
- van Burik, J.A., S.L. Carter, A.G. Freifeld, K.P. High, K.T. Godder, G.A. Papanicolaou, A.M. Mendizabal, J.E. Wagner, S. Yanovich, and N.A. Kernan. 2007. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. *Biol. Blood Marrow Transplant.* 13:1487–1498. doi:10.1016/j.bbmt.2007.08.049
- Veldhoen, M., R.J. Hocking, C.J. Atkins, R.M. Locksley, and B. Stockinger. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. *Immunity.* 24:179–189. doi:10.1016/j.immuni.2006.01.001
- Wang, L., T. Yi, M. Kortylewski, D.M. Pardoll, D. Zeng, and H. Yu. 2009. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. *J. Exp. Med.* 206:1457–1464. doi:10.1084/jem.20090207
- Wilhelm, M., V. Kunzmann, S. Eckstein, P. Reimer, F. Weissinger, T. Ruediger, and H.P. Tony. 2003. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. *Blood.* 102:200–206. doi:10.1182/blood-2002-12-3665
- Zitvogel, L., O. Kepp, and G. Kroemer. 2010. Decoding cell death signals in inflammation and immunity. *Cell.* 140:798–804. doi:10.1016/j.cell.2010.02.015